PMA supplement
P230026 S001: Lacrosse NSE ALPHA Coronary Dilatation Catheter
FDA PMA supplement · Normal 180 Day Track No User Fee · NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.)
Key facts
| Original PMA | P230026 |
|---|---|
| Supplement number | S001 |
| Supplement type | Normal 180 Day Track No User Fee |
| Reason for the supplement | Postapproval Study Protocol |
| Trade name | Lacrosse NSE ALPHA Coronary Dilatation Catheter |
| Generic name | Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring |
| Applicant | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) |
| Product code | NWX |
| Received date | Jul 3, 2024 |
| Decision date | Aug 2, 2024 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: